Drug Trial Radar · NCT07157254
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
55
Actual
Start
Oct 13, 2025
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of the study is to evaluate the safety and efficacy of GTX-102 in participants with Angelman syndrome.
Conditions
- Angelman Syndrome
Interventions
No interventionOther
During the no treatment period participants do not receive any study drug
GTX-102Drug
antisense oligonucleotide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subprotocol A/B/C/D: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Severe Events, and Events Related to Investigational Product, Procedure, and PremedicationTime frame: Up to Day 506
- Subprotocol A Only: Bayley-4 Cognitive Without Caregiver Input Raw Score Change from Baseline at Day 338Time frame: Baseline, Day 338
- Subprotocol B/D Only: Multidomain Responder Index (MDRI) Net Response at Day 338Time frame: Baseline, Day 338
- Subprotocol C Only: MDRI Net Response at Day 338Time frame: Baseline, Day 338
Locations
21 sites in 8 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California
Rush University Medical Center
Chicago, Illinois
Kennedy Kreiger Institute
Baltimore, Maryland
Clinical Trial Site
Kansas City, Missouri
Rare Disease Research
Hillsborough, North Carolina
Akron Children's Hospital
Akron, Ohio
UT Health Austin
Austin, Texas
Carum Research Inc.
Dallas, Texas
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
Hospital de Crianças César Pernetta e Hospital Pequeno Príncipe
Curitiba, Paraná, Brazil
Casa dos Raros
Santa Cecília, Porto Alegre, Brazil
Hopital de la Timone
Marseille, France
Necker-Enfants Malades Hospital
Paris, France
Sheba Medical Center
Ramat Gan, Israel
Azienda Ospedaliera Universitaria Meyer IRCCS
Florence, Italy
Fondazione IRCCS Istituto Neurologico C. Besta
Milan, Italy
Clinical Trial Site
Rome, Italy
Hospital de Santa Maria
Lisbon, Portugal
Hospital Santa Joao
Porto, Portugal
Clinical Trial Site
London, United Kingdom
University of Oxford
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.